Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery

OBJECTIVES:

Primary

- To determine the proportion of patients with recurrent, metastatic, or primary
unresectable adrenocortical carcinoma who achieve an objective response to
R-(-)-gossypol acetic acid.

Secondary

- To evaluate the safety of this drug in these patients.

- To determine the progression-free and overall survival of these patients.

OUTLINE: This is a multicenter study.

Patients receive oral R-(-)-gossypol acetic acid once daily on days 1-21. Treatment repeats
every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for up to 2
years.